Statin-associated neuromyotoxicity

Drugs of Today

Volumn 41, Issue 4, 2005, Pages 267-293

  Baker, Steven K ^a   Tarnopolsky, Mark A ^a,b  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; COLCHICINE; CYCLOSPORIN; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DIGOXIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID; LONAFARNIB; MACROLIDE; MEVALONIC ACID; MEVINOLIN; MIBEFRADIL; PITAVASTATIN; PRAVASTATIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PYRROLE; ROSUVASTATIN; SIMVASTATIN; TIPIFARNIB; UBIDECARENONE; WARFARIN;

BIOSYNTHESIS; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; DRUG METABOLISM; ELECTRON TRANSPORT; ENZYME REGULATION; EXERCISE; GUILLAIN BARRE SYNDROME; HUMAN; HYPERCALCEMIA; LOW DRUG DOSE; MELAS SYNDROME; MUSCLE DISEASE; MUSCLE INJURY; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NEUROMUSCULAR DISEASE; NEUROTOXICITY; NONHUMAN; OPHTHALMOPLEGIA; POLYNEUROPATHY; REVIEW; RHABDOMYOLYSIS;

ACYL COENZYME A; ADVERSE DRUG REACTION REPORTING SYSTEMS; CHOLESTEROL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MEVALONIC ACID; MUSCULAR DISEASES; PERIPHERAL NERVOUS SYSTEM DISEASES; RHABDOMYOLYSIS; TERPENES; UBIQUINONE;

EID: 22244462386     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2005.41.4.908565     Document Type: Review

References (255)

1. Igel, M., Sudhop, T., von Bergmann, K. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol 2001, 57: 357-64.
2. Dromer, C., Vedrenne, C., Billey, T., Pages, M., Fournie, B., Fournie, A. Rhabdomyolysis due to simvastin. Apropos of a case with review of the literature. Rev Rhum Mal Osteoartic 1992, 59: 281-3.
3. Maron, D.J., Fazio, S., Linton, M.F. Current perspectives on statins. Circulation 2000, 101: 207-13.
4. Baker, S.K., Tarnopolsky, M.A. Statin myopathies: Pathophysiologic and clinical perspectives. Clin Invest Med 2001, 24: 258-72.
5. Omar, M.A., Wilson, J.P., Cox, T.S. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001, 35: 1096-107.
6. Tomlinson, B., Chan, P., Lan, W. How well tolerated are lipid-lowering drugs? Drugs Aging 2001, 18: 665-83.
7. Evans, M., Rees, A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: Are all statins the same? Drug Saf 2002, 25: 649-63.
8. Bolego, C., Baetta, R., Bellosta, S., Corsini, A., Paoletti, R. Safety considerations for statins. Curr Opin Lipidol 2002, 13: 637-44.
9. Sinzinger, H., Wolfram, R., Peskar, B.A. Muscular side effects of statins. J Cardiovasc Pharmacol 2002, 40: 163-71.
10. Ballantyne, C.M., Corsini, A., Davidson, M.H. et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003, 163: 553-64.
11. Farmer, J.A. Statins and myotoxicity. Curr Atheroscler Rep 2003, 5: 96-100.
12. Thompson, P.D., Clarkson, P., Karas, R.H. Statin-associated myopathy. JAMA 2003, 289: 1681-90.
13. The changing face of heart disease in Canada 2000. Executive summary. Ottawa: Health Canada, 2000 (accessed April 30, 2003).
14. Argov, Z. Drug-induced myopathies. Curr Opin Neurol 2000, 13: 541-5.
15. Knopp, R.H. Drug treatment of lipid disorders. N Engl J Med 1999, 341: 498-511.
16. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344: 1383-9.
17. Sacks, F.M., Pfeffer, M.A., Moye, L.A. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996, 335: 1001-9.
18. Shepherd, J., Cobbe, S.M., Ford, I. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333: 1301-7.
19. Sever, P.S., Dahlof, B., Poulter, N.R. et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003, 361: 1149-58.
20. Herrington, D.M., Vittinghoff, E., Lin, F. et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation 2002, 105:2962-7.
21. Genest, J., Frohlich, J., Fodor, G., McPherson, R. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: Summary of the 2003 update. CMAJ 2003, 169: 921-4.
22. Bottorff, M.B. Underidentification and undertreatment issues. J Manag Care Pharm 2003, 9 (1 Suppl.): 6-8.
23. Mantel-Teeuwisse, A.K., Verschuren, W.M., Klungel, O.H. et al. Undertreatment of hypercholesterolaemia: A population-based study. Br J Clin Pharmacol 2003, 55: 389-97.
24. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002, 360: 7-22.
25. Prasad, G.V., Wong, T., Meliton, G., Bhaloo, S. Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient. Transplantation 2002, 74: 1200-1.
26. Smith, D.J., Olive, K.E. Chinese red rice-induced myopathy. South Med J 2003, 96: 1265-7.
27. Vaughan, C.J., Murphy, M.B., Buckley, B.M. Statins do more than just lower cholesterol. Lancet 1996, 348: 1079-82.
28. Lefer, A.M., Scalia, R., Lefer, D.J. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res 2001, 49: 281-7.
29. Werner, N., Nickenig, G., Laufs, U. Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res Cardiol 2002, 97: 105-16.
30. Simons, M. Molecular multitasking: Statins lead to more arteries, less plaque. Nat Med 2000, 6: 965-6.
31. Schwartz, G.G., Olsson, A.G., Ezekowitz, M.D. et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA 2001, 285: 1711-8.
32. Alberts, M.J. Suppression of recurrent transient ischemic attacks by a statin agent. Neurology 2001, 56: 531-2.
33. Kennedy, J., Eliasziw, M., Hill, M., Buchan, A. The Fast Assessment of Stroke and Transient ischemic attack to prevent Early Recurrence (FASTER) Trial. Sem Cerebrovasc Dis 2003, 3: 25-30.
34. Simons, M., Schwarzler, F., Lutjohann, D. et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 2002, 52: 346-50.
35. Fassbender, K., Simons, M., Bergmann, C. et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides A-beta 42 and A-beta 40 in vitro and in vivo. Proc Natl Acad Sci USA 2001, 98: 5856-61.
36. Youssef, S., Stuve, O., Patarroyo, J.C. et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002, 420: 78-84.
37. Schmidmaier, R., Baumann, P., Simsek, M., Dayyani, R, Emmerich, B., Meinhardt, G. The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion mediated drug resistance (CAM-DR) in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Blood 2004, 104: 1825-32.
38. Isley, W.L. Pitavastatin (NK-104), a new HMG-CoA reductase inhibitor. Drugs Today (Barc) 2001, 37: 587-94.
39. Bradford, R.H., Shear, C.L., Chremos, A.N. et al. Expanded clinical evaluation of lovastatin (EXCEL) study results: Two-year efficacy and safety follow-up. Am J Cardiol 1994, 74: 667-73.
40. Frishman, W.H., Rapier, R.C. Lovastatin: An HMG-CoA reductase inhibitor for lowering cholesterol. Med Clin North Am 1989, 73: 437-48.
41. Haria, M., McTavish, D. Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease. Drugs 1997, 53: 299-336.
42. Lennernas, H., Fager, G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 1997, 32: 403-25.
43. Plosker, G.L., McTavish, D. Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia. Drugs 1995, 50: 334-63.
44. Plosker, G.L., Wagstaff, A.J. Fluvastatin: A review of its pharmacology and use in the management of hypercholesterolaemia. Drugs 1996, 51: 433-59.
45. Chapman, M.J., McTaggart, F. Optimizing the pharmacology of statins: Characteristics of rosuvastatin. Atheroscler Suppl 2002, 2: 33-6, discussion 6-7.
46. Sirtori, C.R., Manzoni, C., Lovati, M.R. Mechanisms of lipid-lowering agents. Cardiology 1991, 78: 226-35.
47. Staffa, J.A., Chang, J., Green, L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002, 346: 539-40.
48. von Richter, O., Burk, O., Fromm, M.F., Thon, K.P., Eichelbaum, M., Kivisto, K.T. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: A comparative analysis in paired tissue specimens. Clin Pharmacol Ther 2004, 75: 172-83.
49. Kantola, T., Kivisto, K.T., Neuvonen, P.J. Grape-fruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998, 63: 397-402.
50. Hsiang, B., Zhu, Y., Wang, Z. et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 1999, 274: 37161-8.
51. Nagasawa, K., Nagai, K., Ishimoto, A., Fujimoto, S. Transport mechanism for lovastatin acid in bovine kidney NBL-1 cells: Kinetic evidences imply involvement of monocarboxylate transporter 4. Int J Pharm 2003, 262: 63-73.
52. Wilson, M.C., Jackson, V.N., Heddle, C. et al. Lactic acid efflux from white skeletal muscle is catalyzed by the monocarboxylate transporter isoform MCT3. J Biol Chem 1998, 273: 15920-6.
53. Halestrap, A.P., Meredith, D. The SLC16 gene family - from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond. Pflugers Arch 2004, 447: 619-28.
54. Fujino, H., Yamada, I., Shimada, S., Yoneda, M., Kojima, J. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: Human UDP-glucuronosyltransferase enzymes involved in lactonization. Xenobiotica 2003, 33: 27-41.
55. Nezasa, K., Higaki, K., Matsumura, T. et al. Liver-specific distribution of rosuvastatin in rats: Comparison with pravastatin and simvastatin. Drug Metab Dispos 2002, 30: 1158-63.
56. Cheng, H., Rogers, J.D., Sweany, A.E. et al. Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin. Pharm Res 1992, 9: 1629-33.
57. Muck, W. Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions. Drugs 1998, 56 (Suppl 1): 15-23, discussion 33.
58. Stern, R.H., Gibson, D.M., Whitfield, L.R. Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction. Eur J Clin Pharmacol 1998, 53: 475-8.
59. Fischer, V., Johanson, L., Heitz, F. et al. The 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor fluvastatin: Effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab Dispos 1999, 27: 410-6.
60. Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R., Bernini, F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999, 84: 413-28.
61. Aboushadi, N., Shackelford, J.E., Jessani, N., Gentile, A., Krisans, S.K. Characterization of peroxisomal 3-hydroxy-3-methylglutaryl coenzyme A reductase in UT2 cells: Sterol biosynthesis, phosphorylation, degradation, and statin inhibition. Biochemistry 2000, 39: 237-47.
62. Aboushadi, N., Engfelt, W.H., Paton, V.G., Krisans, S.K. Role of peroxisomes in isoprenoid biosynthesis. J Histochem Cytochem 1999, 47: 1127-32.
63. Ma, P.T., Gil, G., Sudhof, T.C., Bilheimer, D.W., Goldstein, J.L., Brown, M.S. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl Acad Sci USA 1986, 83: 8370-4.
64. Feramisco, J.D., Goldstein, J.L., Brown, M.S. Membrane topology of human insig-1, a protein regulator of lipid synthesis. J Biol Chem 2004, 279: 8487-96.
65. Vidon, C., Boucher, P., Cachefo, A., Peroni, O., Diraison, F., Beylot, M. Effects of isoenergetic high-carbohydrate compared with high-fat diets on human cholesterol synthesis and expression of key regulatory genes of cholesterol metabolism. Am J Clin Nutr 2001, 73: 878-84.
66. Ness, G.C., Zhao, Z., Wiggins, L. Insulin and glucagon modulate hepatic 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity by affecting immunoreactive protein levels. J Biol Chem 1994, 269: 29168-72.
67. Ness, G.C., Chambers, C.M. Feedback and hormonal regulation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase: The concept of cholesterol buffering capacity. Proc Soc Exp Biol Med 2000, 224: 8-19.
68. Beg, Z.H., Brewer, H.B., Jr. Modulation of rat liver 3-hydroxy-3- methylglutaryl-CoA reductase activity by reversible phosphorylation. Fed Proc 1982, 41: 2634-8.
69. Hung, Y.T., Yeung, V.T. Hypothyroidism presenting as hypercholesterolaemia and simvastatin-induced myositis. Hong Kong Med J 2000, 6: 423-4.
70. Dimitriadis, G.D., Leighton, B., Parry-Billings, M., West, D., Newsholme, E.A. Effects of hypothyroidism on the sensitivity of glycolysis and glycogen synthesis to insulin in the soleus muscle of the rat. Biochem J 1989, 257: 369-73.
71. McKeran, R.O., Slavin, G., Ward P., Paul, E., Mair, W.G. Hypothyroid myopathy. A clinical and pathological study. J Pathol 1980, 132: 35-54.
72. Siciliano, G., Monzani, F., Manca, M.L. et al. Human mitochondrial transcription factor A reduction and mitochondrial dysfunction in Hashimoto's hypothyroid myopathy. Mol Med 2002, 8: 326-33.
73. Combaret, L., Taillandier, D., Attaix, D. Nutritional and hormonal control of protein breakdown. Am J Kidney Dis 2001, 37 (1 Suppl. 2): S108-11.
74. Waclawik, A.J., Lindal, S., Engel, A.G. Experimental lovastatin myopathy. J Neuropathol Exp Neurol 1993, 52: 542-9.
75. Takacs, O., Heiner, L., Guba, F. Changes in the sarcoplasmic proteins of skeletal muscles induced by experimental steroid myopathy. Acta Physiol Acad Sci Hung 1980, 55: 121-8.
76. Seene, T., Umnova, M., Alev, K., Pehme, A. Effect of glucocorticoids on contractile apparatus of rat skeletal muscle. J Steroid Biochem 1988, 29: 313-7.
77. Sinensky, M. Recent advances in the study of prenylated proteins. Biochim Biophys Acta 2000, 1484: 93-106.
78. Zhang, F.L., Casey, P.J. Protein prenylation: Molecular mechanisms and functional consequences. Annu Rev Biochem 1996, 65: 241-69.
79. Beyer, R.E. An analysis of the role ofcoenzyme Q in free radical generation and as an antioxidant. Biochem Cell Biol 1992, 70: 390-403.
80. Ernster, L., Dallner, G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta 1995, 1271: 195-204.
81. Takai, Y., Sasaki, T., Matozaki, T. Small GTP-binding proteins. Physiol Rev 2001, 81: 153-208.
82. Epstein, W.W., Lever, D., Leining, L.M., Bruenger, E., Rilling, H.C. Quantitation of prenylcysteines by a selective cleavage reaction. Proc Natl Acad Sci USA 1991, 88: 9668-70.
83. Bellosta, S., Bernini, F., Ferri, N. et al. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 1998, 137 (Suppl.): S101-9.
84. Flint, O.P., Masters, B.A., Gregg, R.E., Durham, S.K. HMG CoA reductase inhibitor-induced myotoxicity: Pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture. Toxicol Appl Pharmacol 1997, 145: 99-110.
85. van Vliet, A.K., Negre-Aminou, P., van Thiel, G.G., Bolhuis, P.A., Cohen, L.H. Action of lovastatin, simvastatin, and pravastatin on sterol synthesis and their antiproliferative effect in cultured myoblasts from human striated muscle. Biochem Pharmacol 1996, 52: 1387-92.
86. Veerkamp, J.H., Smit, J.W., Benders, A.A., Oosterhof, A. Effects of HMG-CoA reductase inhibitors on growth and differentiation of cultured rat skeletal muscle cells. Biochim Biophys Acta 1996, 1315:217-22.
87. Raiteri, M., Arnaboldi, L., McGeady, P. et al. Pharmacological control of the mevalonate pathway: Effect on arterial smooth muscle cell proliferation. J Pharmacol Exp Ther 1997, 281: 1144-53.
88. Bennett, W.E., Drake, A.J. 3rd, Shakir, K.M. Reversible myopathy after statin therapy in patients with normal creatine kinase levels. Ann Intern Med 2003, 138: 436-7.
89. Dujovne, C.A. Side effects of statins: Hepatitis versus "transaminitis"-myositis versus "CPKitis". Am J Cardiol 2002, 89: 1411-3.
90. Tobert, J.A. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988, 62: 28J-34J.
91. Phillips, P.S., Haas, R.H., Bannykh, S. et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002, 137: 581-5.
92. Gambelli, S., Dotti, M.T., Malandrini, A. et al. Mitochondrial alterations in muscle biopsies of patients on statin therapy. J Submicrosc Cytol Pathol 2004, 36: 85-9.
93. England, J.D., Walsh, U.C., Stewart, P., Boyd, I., Rohan, A., Halmagyi, G.M. Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors - simvastatin and pravastatin. Aust N Z J Med 1995, 25: 374-5.
94. Fukami, M., Maeda, N., Fukushige, J. et al. Effects of HMG-CoA reductase inhibitors on skeletal muscles of rabbits. Res Exp Med (Berl) 1993, 193: 263-73.
95. Chucrallah, A., De Girolami, U., Freeman, R., Federman, M. Lovastatin/gemfibrozil myopathy: A clinical, histochemical, and ultrastructural study. Eur Neurol 1992, 32: 293-6.
96. Kogan, A.D., Orenstein, S. Lovastatin-induced acute rhabdomyolysis. Postgrad Med J 1990, 66: 294-6.
97. Spach, D.H., Bauwens, U.E., Clark, C.D., Burke, W.G. Rhabdomyolysis associated with lovastatin and erythromycin use. West J Med 1991, 154: 213-5.
98. Bakris, G.L., Lass, N., Gaber, A.O., Jones, J.D., Burnett, J.C. Jr. Radiocontrast medium-induced declines in renal function: A role for oxygen free radicals. Am J Physiol 1990, 258 (1 Pt. 2): F115-20.
99. Baliga, R., Ueda, N., Walker, P.D., Shah, S.V. Oxidant mechanisms in toxic acute renal failure. Am J Kidney Dis 1997, 29: 465-77.
100. Tepel, M., van der Giet, M., Schwarzfeld, C., Laufer, U., Liermann, D., Zidek, W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000, 343: 180-4.
101. Prendergast, B.D., George, C.F. Drug-induced rhabdomyolysis - mechanisms and management. Postgrad Med J 1993, 69: 333-6.
102. Thompson, P.D., Nugent, A.M., Herbert, P.N. Increases in creatine kinase after exercise in patients treated with HMG Co-A reductase inhibitors. JAMA 1990, 264: 2992.
103. Thompson, P.D., Zmuda, J.M., Domalik, L.J., Zimet, R.J., Staggers, J., Guyton, J.R. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism 1997, 46: 1206-10.
104. Unnikrishnan, D., Satish, B. Exertion-induced rhabdomyolysis in a patient on statin therapy. Nephrol Dial Transplant 2005, 20: 244.
105. Sinzinger, H., O'Grady, J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol 2004, 57: 525-8.
106. Clarkson, P.M. Eccentric exercise and muscle damage, Int J Sports Med 1997, 18 (Suppl. 4): S314-7.
107. Lieber, R.L., Schmitz, M.C., Mishra, D.K., Friden, J. Contractile and cellular remodeling in rabbit skeletal muscle after cyclic eccentric contractions. J Appl Physiol 1994, 77: 1926-34.
108. Bifulco, M., Laezza, C., Aloj, S.M., Garbi, C. Mevalonate controls cytoskeleton organization and cell morphology in thyroid epithelial cells. J Cell Physiol 1993, 155: 340-8.
109. Matzno, S., Yamauchi, T., Gohda, M. et al. Inhibition of cholesterol biosynthesis by squalene epoxidase inhibitor avoids apoptotic cell death in L6 myoblasts. J Lipid Res 1997, 38: 1639-48.
110. Meske, V., Albert, F., Richter, D., Schwarze, J., Ohm, T.G. Blockade of HMG-CoA reductase activity causes changes in microtubulestabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: Implications for Alzheimer's disease. Eur J Neurosci 2003, 17: 93-102.
111. Juel, C. Muscle lactate transport studied in sarcolemmal giant vesicles. Biochim Biophys Acta 1991, 1065: 15-20.
112. Roth, D.A. The sarcolemmal lactate transporter: Transmembrane determinants of lactate flux. Med Sci Sports Exerc 1991, 23: 925-34.
113. Bonen. A. The expression of lactate transporters (MCT1 and MCT4) in heart and muscle. Eur J Appl Physiol 2001, 86: 6-11.
114. Bhuiyan, J., Seccombe, D.W. The effects of 3-hydroxy-3-methylglutaryl-CoA reductase inhibition on tissue levels of carnitine and carnitine acyltransferase activity in the rabbit. Lipids 1996, 31: 867-70.
115. Arduini, A., Peschechera, A., Giannessi, F., Carminati, P. Improvement of statin-associated myotoxicity by L-carnitine. J Thromb Haemost 2004, 2: 2270-1.
116. Sinzinger, H., Lupattelli, G., Chehne, F., Oguogho, A., Furberg, C.D. Isoprostane 8-epi-PGF2-alpha is frequently increased in patients with muscle pain and/or CK-elevation after HMG-Co-enzyme-A-reductase inhibitor therapy. J Clin Pharm Ther 2001, 26: 303-10.
117. Sinzinger, H., Lupattelli, G., Chehne, R Increased lipid peroxidation in a patient with CK-elevation and muscle pain during statin therapy. Atherosclerosis 2000, 153: 255-6.
118. Holt, S., Reeder, B., Wilson, M. et al. Increased lipid peroxidation in patients with rhabdomyolysis. Lancet 1999, 353: 1241.
119. Tarnopolsky, M.A., Mahoney, D.J., Vajsar, J. et al. Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy. Neurology 2004, 62: 1771-7.
120. Rodriguez, M.C., Tarnopolsky, M.A. Patients with dystrophinopathy show evidence of increased oxidative stress. Free Radic Biol Med 2003, 34: 1217-20.
121. Sinzinger, H. Does vitamin E beneficially affect muscle pains during HMG-Co-enzyme-A-reductase inhibitors without CK-elevation? Atherosclerosis 2000, 149: 225.
122. Chariot, P., Abadia, R., Agnus, D., Danan, C., Charpentier, C., Gherardi, R.K. Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am J Med 1993, 94: 109-10.
123. Krivosic-Horber, R., Depret, T., Wagner, J.M., Maurage, C.A. Malignant hyperthermia susceptibility revealed by increased serum creatine kinase concentrations during statin treatment. Eur J Anaesthesiol 2004, 21: 572-4.
124. Parmar, B., Francis, P.J., Ragge, N.K. Statins, fibrates, and ocular myasthenia. Lancet 2002, 360: 717.
125. Cartwright, M.S., Jeffery, D.R., Nuss, G.R., Donofrio, P.D. Statin-associated exacerbation of myasthenia gravis. Neurology 2004, 63: 2188.
126. Guis, S., Bendahan, D., Kozak-Ribbens, G. et al. Rhabdomyolysis and myalgia associated with anticholesterolemic treatment as potential signs of malignant hyperthermia susceptibility. Arthritis Rheum 2003, 49: 237-8.
127. Delgado-Lopez, F., Bautista-Lorite, J., Villamil-Fernandez, F. Worsening for using statin in carnitine palmityol transferase deficiency myopathy. Rev Neurol 2004, 38: 1095.
128. Livingstone, C., Al Riyami, S., Wilkins, P., Ferns, G.A. McArdle's disease diagnosed following statin-induced myositis, Ann Clin Biochem 2004, 41 (Pt. 4): 338-40.
129. Baker, S.K., Vladutiu, G.D., Tarnopolsky, M.A. McArdle disease unmasked by statin exposure. Muscle Nerve 2003 (Suppl. 12): S73-S4.
130. Vasconcelos, O.M., Campbell, W.W. Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake. Muscle Nerve 2004, 30: 803-7.
131. Huynh, T., Cordato, D., Yang, F. et al. HMG CoA reductase-inhibitor- related myopathy and the influence of drug interactions. Intern Med J 2002, 32: 486-90.
132. Giordano, N., Senesi, M., Mattii, G., Battisti, E., Villanova, M., Gennari, C. Polymyositis associated with simvastatin. Lancet 1997, 349: 1600-1.
133. Hill, C., Zeitz, C., Kirkham, B. Dermatomyositis with lung involvement in a patient treated with simvastatin. Aust NZJ Med 1995, 25: 745-6.
134. Khattak, F.H., Morris, I.M., Branford, W.A. Simvastatin-associated dermatomyositis. Br J Rheumatol 1994, 33: 199.
135. Rodriguez-Garcia, J.L., Serrano Commino, M. Lovastatin-associated dermatomyositis. Postgrad Med J 1996, 72: 694.
136. Dai, Z., Luo, X., Xie, H., Peng, H.B. The actin-driven movement and formation of acetylcholine receptor clusters. J Cell Biol 2000, 150: 1321-34.
137. Bloch, R.J. Acetylcholine receptor clustering in rat myotubes: Requirement for CA2+ and effects of drugs which depolymerize microtubules. J Neurosci 1983, 3: 2670-80.
138. Tsao, C.Y., Mendell, J.R. Combined partial deficiencies of carnitine palmitoyltransferase II and mitochondrial complex I presenting as increased serum creatine kinase level. J Child Neurol 2002, 17: 304-6.
139. Folkers, K., Langsjoen, P., Willis, R. et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci USA 1990, 87: 8931-4.
140. Willis, R.A., Folkers, K., Tucker, J.L., Ye, C.Q., Xia, L.J., Tamagawa, H. Lovastatin decreases coenzyme Q levels in rats. Proc Natl Acad Sci USA 1990, 87: 8928-30.
141. Kaplan, L., Fearn, J., Lasarewski, P., Stein, E. Serum ubiquinone Q10 levels: Effects of cholesterol lowering drugs (Abstr.). Clin Chem 1990, 36: 963.
142. Ghirlanda, G., Oradei, A., Manto, A. et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: A double-blind, placebo-controlled study. J Clin Pharmacol 1993, 33: 226-9.
143. Elmberger, P.G., Kalen, A., Lund, E. et al. Effects of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolemia. J Lipid Res 1991, 32: 935-40.
144. De Pinieux, G., Chariot, P., Ammi-Said, M. et al. Lipid-lowering drugs and mitochondrial function: Effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol 1996, 42: 333-7.
145. Forsmark-Andree, P., Lee, C.P., Dallner, G., Ernster, L. Lipid peroxidation and changes in the ubiquinone content and the respiratory chain enzymes of submitochondrial particles. Free Radic Biol Med 1997, 22: 391-400.
146. Noack, H., Kube, U., Augustin, W. Relations between tocopherol depletion and coenzyme Q during lipid peroxidation in rat liver mitochondria. Free Radic Res 1994, 20: 375-86.
147. Mutoh, T., Kumano, T., Nakagawa, H., Kuriyama, M. Role of tyrosine phosphorylation of phospholipase C gammal in the signaling pathway of HMG-CoA reductase inhibitor-induced cell death of L6 myoblasts. FEBS Lett 1999, 446: 91-4.
148. Nakagawa, H., Mutoh, T., Kumano, T., Kuriyama, M. HMG-CoA reductase inhibitor-induced L6 myoblast cell death: Involvement of the phosphatidylinositol 3-kinase pathway. FEBS Lett 1998, 438: 289-92.
149. Kagan, T., Davis, C., Lin, L., Zakeri, Z. Coenzyme Q10 can in some circumstances block apoptosis, and this effect is mediated through mitochondria. Ann NY Acad Sci 1999, 887: 31-47.
150. Tomasetti, M., Littarru, G.P., Stocker, R., Alleva, R. Coenzyme Q10 enrichment decreases oxidative DNA damage in human lymphocytes. Free Radic Biol Med 1999, 27: 1027-32.
151. Tomasetti, M., Alleva, R., Borghi, B., Collins, A. R. In vivo supplementation with coenzyme Q10 enhances the recovery of human lymphocytes from oxidative DNA damage. Faseb J 2001, 15: 1425-7.
152. Artuch, R., Colome, C., Vilaseca, M.A., Pineda, M., Campistol, J. Ubiquinone: Metabolism and functions. Ubiquinone deficiency and its implication in mitochondrial encephalopathies. Treatment with ubiquinone. Rev Neurol 1999, 29: 59-63.
153. Musumeci, O., Naini, A., Slonim, A.E. et al. Familial cerebellar ataxia with muscle coenzyme Q10 deficiency. Neurology 2001, 56: 849-55.
154. Rotig, A., Appelkvist, E.L., Geromel, V. et al. Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. Lancet 2000, 356: 391-5.
155. Sobreira, C., Hirano, M., Shanske, S. et al. Mitochondrial encephalomyopathy with coenzyme Q10 deficiency. Neurology 1997, 48: 1238-43.
156. Judy, W.V., Stogsdill, W.W., Folkers, K. Myocardial preservation by therapy with coenzyme Q10 during heart surgery. Clin Investig 1993, 71 (8Suppl.): S155-61.
157. Manzoli, U., Rossi, E., Littarru, G.P. et al. Coenzyme Q10 in dilated cardiomyopathy. Int J Tissue React 1990, 12: 173-8.
158. Sole, M.J., Jeejeebhoy, K.N. Conditioned nutritional requirements and the pathogenesis and treatment of myocardial failure. Curr Opin Clin Nutr Metab Care 2000, 3: 417-24.
159. Abe, K., Fujimura, H., Nishikawa, Y. et al. Marked reduction in CSF lactate and pyruvate levels after CoQ therapy in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). Acta Neurol Scand 1991, 83: 356-9.
160. Nambudiri, A.M., Ranganathan, S., Rudney, H. The role of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in the regulation of ubiquinone synthesis in human fibroblasts. J Biol Chem 1980, 255: 5894-9.
161. Walravens, P.A., Greene, C., Frerman, F.E. Lovastatin, isoprenes, and myopathy. Lancet 1989, 2: 1097-8.
162. Lam, C.W., Lau, C.H., Williams, J.C., Chan, Y.W., Wong, L.J. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) triggered by valproate therapy. Eur J Pediatr 1997, 156: 562-4.
163. Chan, A., Reichmann, H., Kogel, A., Beck, A., Gold, R. Metabolic changes in patients with mitochondrial myopathies and effects of coenzyme Q10 therapy. J Neurol 1998, 245: 681-5.
164. Abe, K., Matsuo, Y., Kadekawa, J., Inoue, S., Yanagihara, T. Effect of coenzyme Q10 in patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): Evaluation by noninvasive tissue oximetry. J Neurol Sci 1999, 162: 65-8.
165. Laaksonen, R., Jokelainen, K., Laakso, J. et al. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol 1996, 77: 851-4.
166. Laaksonen, R., Jokelainen, K., Sahi, T., Tikkanen, M.J., Himberg, J.J. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during shortterm simvastatin treatment in humans. Clin Pharmacol Ther 1995, 57: 62-6.
167. Thibault, A., Samid, D., Tompkins, A.C. et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 1996, 2: 483-91.
168. Passi, S., Stancato, A., Aleo, E., Dmitrieva, A., Littarru, G.P. Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA. Biofactors 2003, 18: 113-24.
169. Elmberger, P.G., Kalen, A., Brunk, U.T., Dallner, G. Discharge of newly-synthesized dolichol and ubiquinone with lipoproteins to rat liver perfusate and to the bile. Lipids 1989, 24: 919-30.
170. Johansen, K., Theorell, H., Karlsson, J., Diamant, B., Folkers, K. Coenzyme Q10, alphatocopherol and free cholesterol in HDL and LDL fractions. Ann Med 1991, 23: 649-56.
171. Laaksonen, R., Ojala, J.P., Tikkanen, M.J., Himberg, J.J. Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1994, 46: 313-7.
172. Mabuchi, H., Haba, T., Tatami, R. et al. Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia. N Engl J Med 1981, 305: 478-82.
173. Rundek, T., Naini, A., Sacco, R., Coates, K., DiMauro, S. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neurol 2004, 61: 889-92.
174. Schaefer, W.H., Lawrence, J.W., Loughlin, A.F. et al. Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats. Toxicol Appl Pharmacol 2004, 194: 10-23.
175. Maltese, W.A., Aprille, J.R. Relation of mevalonate synthesis to mitochondrial ubiquinone content and respiratory function in cultured neuroblastoma cells. J Biol Chem 1985, 260: 11524-9.
176. Beyer, R.E. The participation of coenzyme Q in free radical production and antioxidation. Free Radic Biol Med 1990, 8: 545-65.
177. Lankin, V.Z., Tikhaze, A.K., Kaminnaia, V.I., Kaminnyi, A.I., Konovalova, G.G., Kukharchuk, V.V. Intensification in vivo of free radical oxidation of low density lipoproteins in plasma from patients with myocardial ischemia treated by HMG-CoA-reductase pravastatin and suppression of lipid peroxidation by ubiquinone Q10. Biull Eksp Biol Med 2000, 129: 176-9.
178. Sinzinger, H., Chehne, F., Lupattelli, G. Oxidation injury in patients receiving HMG-CoA reductase inhibitors: Occurrence in patients without enzyme elevation or myopathy. Drug Saf 2002, 25: 877-83.
179. Ucar, M., Mjorndal, T., Dahlqvist, R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 2000, 22: 441-57.
180. Physicians' Desk Reference, 56th ed. Medical Economics: Montvale, NJ 2002.
181. Omar, M.A., Wilson, J.P. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002, 36: 288-95.
182. Scott, H.D., Rosenbaum, S.E., Waters, W.J. et al. Rhode Island physicians' recognition and reporting of adverse drug reactions. RI Med J 1987, 70: 311-6.
183. Vu, D., Murty, M., McMorran, M. Statins: Rhabdomyolysis and myopathy. Canadian ADR Newsletter 2002, 12: 1-3.
184. London, S.F., Gross, K.F., Ringel, S.P. Cholesterol-lowering agent myopathy (CLAM). Neurology 1991, 41: 1159-60.
185. Pierce, L.R., Wysowski, O.K., Gross, T.P. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990, 264: 71-5.
186. Yeagle, P.L. Modulation of membrane function by cholesterol. Biochimie 1991, 73: 1303-10.
187. Kwiecinski, H., Lehmann-Horn, F., Rudel, R. Drug-induced myotonia in human intercostal muscle. Muscle Nerve 1988, 11: 576-81.
188. Conte-Camerino, D., Tortorella, V., Ferranini, E., Bryant, S.H. The toxic effects of clofibrate and its metabolite on mammalian skeletal muscle: An electrophysiological study. Arch Toxicol Suppl 1984, 7: 482-4.
189. Sonoda, Y., Gotow, T., Kuriyama, M., Nakahara, K., Arimura, K., Osame, M. Electrical myotonia of rabbit skeletal muscles by HMG-CoA reductase inhibitors. Muscle Nerve 1994, 17: 891-7.
190. FitzPatrick, D.R., Keeling, J.W., Evans, M.J. et al. Clinical phenotype of desmosterolosis. Am J Med Genet 1998, 75: 145-52.
191. Ryan, A.K., Bartlett, K., Clayton, P. et al. Smith-Lemli-Opitz syndrome: A variable clinical and biochemical phenotype. J Med Genet 1998, 35: 558-65.
192. Seller, M.J., Flinter, F.A., Docherty, Z., Fagg, N., Newbould, M. Phenotypic diversity in the Smith-Lemli-Opitz syndrome. Clin Dysmorphol 1997, 6: 69-73.
193. Andersson, H.C., Kratz, L., Kelley, R. Desmosterolosis presenting with multiple congenital anomalies and profound developmental delay. Am J Med Genet 2002, 113: 315-9.
194. Hoffmann, G.F., Charpentier, C., Mayatepek, E. et al. Clinical and biochemical phenotype in 11 patients with mevalonic aciduria. Pediatrics 1993, 91: 915-21.
195. Di Giovanni, S., Mirabella, M., Spinazzola, A. et al. Coenzyme Q10 reverses pathological phenotype and reduces apoptosis in familial CoQ10 deficiency. Neurology 2001, 57: 515-8.
196. Ogasahara, S., Engel, A.G., Frens, D., Mack, D. Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy. Proc Natl Acad Sci USA 1989, 86: 2379-82.
197. Van Maldergem, L., Trijbels, F., DiMauro, S. et al. Coenzyme Q-responsive Leigh's encephalopathy in two sisters. Ann Neurol 2002, 52: 750-4.
198. Flint, O.P., Masters, B.A., Gregg, R.E., Durham, S.K. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol Appl Pharmacol 1997, 145: 91-8.
199. Wolda, S.L., Glomset, J.A. Evidence for modification of lamin B by a product of mevalonic acid. J Biol Chem 1988, 263: 5997-6000.
200. Beck, L.A., Hosick, T.J., Sinensky, M. Incorporation of a product of mevalonic acid metabolism into proteins of Chinese hamster ovary cell nuclei. J Cell Biol 1988, 107: 1307-16.
201. Farnsworth, C.C., Wolda, S.L., Gelb, M.H., Glomset, J.A. Human lamin B contains a farnesylated cysteine residue. J Biol Chem 1989, 264: 20422-9.
202. Ostlund, C., Worman, H.J. Nuclear envelope proteins and neuromuscular diseases. Muscle Nerve 2003, 27: 393-406.
203. Moosmann, B., Behl, C. Selenoprotein synthesis and side-effects of statins. Lancet 2004, 363: 892-4.
204. Warner, G.J., Berry, M.J., Moustafa, M.E., Carlson, B.A., Hatfield, D.L., Faust, U.R. Inhibition of selenoprotein synthesis by selenocysteine tRNA[Ser]Sec lacking isopentenyladenosine. J Biol Chem 2000, 275: 28110-9.
205. Ferreiro, A., Quijano-Roy, S., Pichereau, C. et al. Mutations of the selenoprotein N gene, which is implicated in rigid spine muscular dystrophy, cause the classical phenotype of multiminicore disease: Reassessing the nosology of early-onset myopathies. Am J Hum Genet 2002, 71: 739-49.
206. Flanigan, K.M., Kerr, L., Bromberg, M.B. et al. Congenital muscular dystrophy with rigid spine syndrome: A clinical, pathological, radiological, and genetic study. Ann Neurol 2000, 47: 152-61.
207. Fidzianska, A., Goebel, H.H., Osborn, M., Lenard, H.G., Osse, G., Langenbeck, U. Mallory body-like inclusions in a hereditary congenital neuromuscular disease. Muscle Nerve 1983, 6: 195-200.
208. Petit, N., Lescure, A., Rederstorff, M. et al. Selenoprotein N: An endoplasmic reticulum glycoprotein with an early developmental expression pattern. Hum Mol Genet 2003, 12: 1045-53.
209. Ervasti, J.M., Campbell, K.P. A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. J Cell Biol 1993, 122: 809-23.
210. Esapa, C.T., Bentham, G.R., Schroder, J.E., Kroger, S., Blake, D.J. The effects of post-translational processing on dystroglycan synthesis and trafficking. FEBS Lett 2003, 555: 209-16.
211. Holt, K.M., Crosbie, R.H., Venzke, D.P., Campbell, K.P. Biosynthesis of dystroglycan: Processing of a precursor propeptide. FEBS Lett 2000, 468: 79-83.
212. Yoshida, A., Kobayashi, K., Manya, H. et al. Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyl-transferase, POMGnT1. Dev Cell 2001, 1: 717-24.
213. Beltran-Valero de Bernabe, D., Currier, S., Steinbrecher, A. et al. Mutations in the O-mannosyltransferase gene POMT1 give rise to the severe neuronal migration disorder Walker-Warburg syndrome. Am J Hum Genet 2002, 71: 1033-43.
214. Kobayashi, K., Nakahori, Y., Miyake, M. et al. An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. Nature 1998, 394: 388-92.
215. Esapa, C.T., Benson, M.A., Schroder, J.E. et al. Functional requirements for fukutin-related protein in the Golgi apparatus. Hum Mol Genet 2002, 11: 3319-31.
216. Van den Steen, P.E., Opdenakker, G., Wormald, M.R., Dwek, R.A., Rudd, P.M. Matrix remodelling enzymes, the protease cascade and glycosylation. Biochim Biophys Acta 2001, 1528: 61-73.
217. Michele, D.E., Barresi, R., Kanagawa, M. et al. Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. Nature 2002, 418: 417-22.
218. Baker, S.K., Goodwin, S., Sur, M., Tarnopolsky, M.A. Cytoskeletal myotoxicity from simvastatin and colchicine. Muscle Nerve 2004, 30: 799-802.
219. Downing, K.H. Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. Annu Rev Cell Dev Biol 2000, 16: 89-111.
220. Kuncl, R.W., Duncan, G., Watson, D., Alderson, K., Rogawski, M.A., Peper, M. Colchicine myopathy and neuropathy. N Engl J Med 1987, 316: 1562-8.
221. Jacobs, M.B. HMG-CoA reductase inhibitor therapy and peripheral neuropathy. Ann Intern Med 1994, 120: 970.
222. Ahmad, S. Lovastatin and peripheral neuropathy. Am Heart J 1995, 130: 1321.
223. Phan, T., McLeod, J.G., Pollard, J.D., Peiris, O., Rohan, A., Halpern, J.P. Peripheral neuropathy associated with simvastatin. J Neurol Neurosurg Psychiatry 1995, 58: 625-8.
224. Ziajka, P.E., Wehmeier, T. Peripheral neuropathy and lipid-lowering therapy. South Med J 1998, 91: 667-8.
225. Jeppesen, U., Gaist, D., Smith, T., Sindrup, S.H. Statins and peripheral neuropathy. Eur J Clin Pharmacol 1999, 54: 835-8.
226. Lo, Y.L., Leoh, T.H., Loh, L.M., Tan, C.E. Statin therapy and small fibre neuropathy: A serial electrophysiological study. J Neural Sci 2003, 208: 105-8.
227. Gaist, D., Garcia Rodriguez, L.A., Huerta, C., Hallas, J., Sindrup, S.H. Are users of lipid-lowering drugs at increased risk of peripheral neuropathy? Eur J Clin Pharmacol 2001, 56: 931-3.
228. Gaist, D., Jeppesen, U., Andersen, M., Garcia Rodriguez, L.A., Hallas, J., Sindrup, S.H. Statins and risk of polyneuropathy: A case-control study. Neurology 2002, 58: 1333-7.
229. Kurzrock, R., Albitar, M., Cortes, J.E. et al. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol 2004, 22: 1287-92.
230. Adjei, A.A., Mauer A., Bruzek, L. et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J Clin Oncol 2003, 21: 1760-6.
231. Cortes, J., Albitar, M., Thomas, D. et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 2003, 101: 1692-7.
232. Crul, M., de Klerk, G.J., Swart, M. et al. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 2002, 20: 2726-35.
233. Karp, J.E., Lancet, J.E., Kaufmann, S.H. et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase 1 clinical-laboratory correlative trial. Blood 2001, 97: 3361-9.
234. Eskens, F.A., Awada, A., Cutler, D.L. et al. Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. J Clin Oncol 2001, 19: 1167-75.
235. Zujewski, J., Horak, I.D., Bol, C.J. et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 2000, 18: 927-41.
236. Johnson, T.E., Zhang, X., Bleicher, K.B. et al. Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone. Toxicol Appl Pharmacol 2004, 200: 237-50.
237. Rajabally, Y.A., Varakantam, V., Abbott, R.J. Disorder resembling Guillain-Barre syndrome on initiation of statin therapy. Muscle Nerve 2004, 30: 663-66.
238. Benito-Leon, J., Porta-Etessam, J. Guillain-Barre syndrome and allopurinol-induced hypersensitivity. Eur Neurol 2001, 45: 186-7.
239. Peltier, A.C., Russell, J.W. Recent advances in drug-induced neuropathies. Curr Opin Neurol 2002, 15: 633-8.
240. Gherardi, R.K., Chariot, P., Vanderstigel, M. et al. Organic arsenic-induced Guillain-Barre-like syndrome due to melarsoprol: A clinical, electrophysiological, and pathological study. Muscle Nerve 1990, 13: 637-45.
241. Yamada, H., Shimizu, T., Tanaka, T., Campbell, K.P., Matsumura, K. Dystroglycan is a binding protein of laminin and merosin in peripheral nerve. FEBS Lett 1994, 352: 49-53.
242. Yamada, H., Denzer, A.J., Hori, H. et al. Dystroglycan is a dual receptor for agrin and laminin-2 in Schwann cell membrane. J Biol Chem 1996, 271: 23418-23.
243. Masaki, T., Matsumura, K., Saito, F. et al. Expression of dystroglycan and laminin-2 in peripheral nerve under axonal degeneration and regeneration. Acta Neuropathol (Berl) 2000, 99: 289-95.
244. Hall, H., Bozic, D., Michel, K., Hubbell, J.A. N-terminal alpha-dystroglycan binds to different extracellular matrix molecules expressed in regenerating peripheral nerves in a protein-mediated manner and promotes neurite extension of PC12 cells. Mol Cell Neurosci 2003, 24: 1062-73.
245. Kunz, S., Sevilla, N., McGavern, D.B., Campbell, K.P., Oldstone, M.B. Molecular analysis of the interaction of LCMV with its cellular receptor [alpha]-dystroglycan. J Cell Biol 2001, 155: 301-10.
246. Matsumura, K., Yamada, H., Saito, F., Sunada, Y, Shimizu, T. Peripheral nerve involvement in merosin-deficient congenital muscular dystrophy and dy mouse. Neuromuscul Disord 1997, 7: 7-12.
247. Saito, F., Moore, S.A., Barresi, R. et al. Unique role of dystroglycan in peripheral nerve myelination, nodal structure, and sodium channel stabilization. Neuron 2003, 38: 747-58.
248. De Sandre-Giovannoli, A., Chaouch, M., Kozlov, S. et al. Homozygous defects in LMNA, encoding lamin A/C nuclear-envelope proteins, cause autosomal recessive axonal neuropathy in human (Charcot-Marie-Tooth disorder type 2) and mouse. Am J Hum Genet 2002, 70: 726-36.
249. Bouhouche, A., Benomar, A., Birouk, N. et al. A locus for an axonal form of autosomal recessive Charcot-Marie-Tooth disease maps to chromosome 1q21.2-q21.3. Am J Hum Genet 1999, 65: 722-7.
250. Goizet, C., Yaou, R.B., Demay, L. et al. A new mutation of the lamin A/C gene leading to autosomal dominant axonal neuropathy, muscular dystrophy, cardiac disease, and leuconychia. J Med Genet 2004, 41: e29.
251. Maehira, F., Miyagi, I., Eguchi, Y. Selenium regulates transcription factor NF-kappa-B activation during the acute phase reaction. Clin Chim Acta 2003, 334: 163-71.
252. Jozsef, L., Filep, J.G. Selenium-containing compounds attenuate peroxynitrite-mediated NF-kappa-B and AP-1 activation and interleukin-8 gene and protein expression in human leukocytes. Free Radic Biol Med 2003, 35: 1018-27.
253. Boyne, R., Arthur, J.R. The response of selenium-deficient mice to Candida albicans infection. J Nutr 1986, 116: 816-22.
254. Beck, M.A., Nelson, H.K., Shi, Q. et al. Selenium deficiency increases the pathology of an influenza virus infection. FASEB J 2001, 15: 1481-3.
255. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (adult treatment panel III). JAMA 2001, 285: 2486-97.